Revolution Medicines Stock Earnings Reports

Revolution Medicines reported a milestone quarter driven by an overwhelmingly positive Phase III readout for daraxonrasib (RASolute 302) in previously treated metastatic pancreatic cancer. Daraxonrasib monotherapy met the primary and key secondary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival and overall survival (a reported 60% reduction in risk of death versus chemotherapy and median overall survival >1 year). Management plans to submit a U.S. NDA (including under the FDA Commissioner’s National Priority Voucher Program), pursue global filings, and has received an FDA safe-to-proceed letter to start an expanded access program. The RASolute 302 data will be presented in the ASCO plenary session. The company is advancing multiple registrational and pivotal studies across indications and settings: first- and second-line pancreatic cancer (including combination and adjuvant trials), expanded/upsized non–small cell lung cancer trials (including daraxonrasib and zoldonrasib programs), a registrational trial of zoldonrasib with KEYNOTE-189, and initiation plans for catalytic RAS(ON) inhibitor RM-055 first-in-human in Q4. Early-stage programs include RMC-5127 (G12V) with expected Phase II dose in H2 2026. Commercial and international launch preparedness is underway, with hires in APAC, Japan and Germany and U.S. field teams being onboarded. Financially, the company ended Q1 2026 with $1.9B in cash and investments and subsequently raised $2.1B net in April. Q1 operating expenses increased substantially (R&D $344M; G&A $101M) and net loss widened to $453.8M, driven by program acceleration, hiring, and a one-time pull-forward of stock-based compensation tied to an equity program change. Full-year 2026 stock-based compensation guidance was raised to $260–$280M, and GAAP operating expense guidance increased to $1.7–$1.8B. Enrollment expansions (e.g., RASolve 301 from 420 to 590 patients) and global footprint expansion are intended to support robust registrational programs. Key near-term catalysts: ASCO plenary presentation, NDA submission activities, expanded access rollout, enrollment progress in frontline registrational trials, and initiation of RM-055 first-in-human study.